Overview
Discounted cash flow
Income / accounting-based
Multiples & assets
Scenario
Toolbox
Weighted blend
$121.89
-9.33% vs spot
Underweight
Spot price
$134.43
Mkt cap $166.9B
subtle cardAnalyst PT consensus
$161.88
+20.42% vs spot
subtle cardMethods covered
19 / 20
16 in blend
subtle cardFootball field
GILD · fair-value range by method
Method comparison
GILD · fair value by valuation framework
| Method | Category | Fair value | Range | vs spot | Weight | Driver | Conf. |
|---|---|---|---|---|---|---|---|
| DCF · FCFF | dcf | $195.65 | $198.69 – $365.24 | +45.54% | 20.1% | WACC 4.7%, g₀=-5.0%, gₗ=2.0% | high |
| DCF · FCFE | dcf | $132.92 | $145.49 – $203.35 | -1.12% | 15.1% | kₑ 5.9%, g₀=-5.0%, gₗ=2.0% | high |
| DDM · Gordon | ddm | $85.24 | $67.99 – $114.22 | -36.59% | — | D₁ 3.29, kₑ 5.9%, gₗ 2.0% | med |
| DDM · H-model | ddm | $55.99 | $67.99 – $91.83 | -58.35% | — | D₀ 3.29, g₀=-5.0%, gₗ=2.0%, H 5y | med |
| DDM · multi-stage | ddm | $71.95 | $61.15 – $82.74 | -46.48% | 5.0% | 5y schedule -5.0% → 2.0%, kₑ 5.9% | high |
| Residual income | income | $34.15 | $30.05 – $38.25 | -74.60% | 10.1% | BV 18.61, ROE 37.6% → kₑ | high |
| EVA / MVA | income | $158.72 | $139.67 – $177.76 | +18.07% | 7.0% | IC 39.6B, WACC 4.7% | high |
| Justified P/E | multiple | $27.69 | $23.54 – $31.85 | -79.40% | 6.0% | Fair P/E 4.1 (payout 47%, kₑ 5.9%, g -5.0%) | med |
| P/E · sector | multiple | $149.16 | $131.26 – $167.06 | +10.96% | 12.1% | EPS 6.78 × peer P/E 22.0 | med |
| Justified P/B | multiple | $72.49 | $61.62 – $83.37 | -46.07% | 5.0% | Fair P/B 3.90 · ROE 37.6%, kₑ 5.9% | high |
| P/S · sector | multiple | $96.89 | $82.35 – $111.42 | -27.93% | 3.0% | Rev/sh 24.22 × peer P/S 4.00 | med |
| EV / EBITDA | multiple | $119.51 | $105.17 – $133.85 | -11.10% | 10.1% | EBITDA × peer 15.0× − ND 17.0B | high |
| EV / EBIT | multiple | $160.98 | $136.83 – $185.13 | +19.75% | 2.0% | EBIT × peer 18.0× − ND | med |
| EV / Sales | multiple | $68.35 | $58.09 – $78.60 | -49.16% | 2.0% | Sales × peer 3.40× − ND | med |
| Earnings power | intrinsic | $164.52 | $144.78 – $184.27 | +22.39% | 0.5% | NOPAT / WACC, no growth | med |
| Graham revised | intrinsic | $56.85 | $48.33 – $65.38 | -57.71% | 0.5% | EPS×(8.5+2g)·4.4/Y | low |
| Lynch P/E=g | intrinsic | $33.90 | $28.81 – $38.98 | -74.78% | 0.5% | PE = g (-5.0) | low |
| Book NAV | asset | $18.61 | $17.68 – $19.54 | -86.16% | 1.0% | (Assets − Liabilities) / Shares | high |
| Liquidation | asset | $5.91 | $5.02 – $6.79 | -95.61% | — | Cash 100% + non-cash 70% − Liab. | low |
| Reverse DCF | reverse | — | — | — | — | Implied g -11.7% · Pessimistic — market pricing decline | high |
Cost-of-capital build-up
CAPM cost of equity, after-tax cost of debt, WACC. Risk-free as of 2026-05-12.
| Risk-free rate (US 10y Treasury)rf | 4.46% |
| Equity beta (0.33)β | × 0.33 |
| Equity risk premiumERP | 4.46% |
| Cost of equity (CAPM)kₑ | 5.94% |
| Pre-tax cost of debtkd | 4.16% |
| Effective tax ratet | 13.1% |
| After-tax cost of debt | 3.62% |
| Equity weight$22.6B | 47.9% |
| Debt weight$24.6B | 52.1% |
| WACC | 4.73% |
Growth assumptions
Blended forward growth used as DCF default; terminal pegged to long-run nominal GDP.
| Analyst forward revenue growthFMP | 3.38% |
| Analyst forward EPS growthFMP | -96.14% |
| Historical 5y revenue CAGRFY | 1.90% |
| Historical 5y EPS CAGRFY | 8.29% |
| Sustainable g (ROE × retention)Δ | 19.93% |
| Blended near-term growth (g₀) | -5.00% |
| Terminal growth (gₗ) | 2.00% |
Sources
- FMP /analyst-estimates— 8 rows(as of 2023-12-31)
- Treasury rates · 10y— 4.46% rf(as of 2026-05-12)
- market_risk_premium · DB— 4.46% ERP(as of 2026-05-13)
- Sector multiple defaults— Healthcare (live sector PE unavailable)
- FMP /price-target-consensus— mean $161.88
This page is generated by a quantitative valuation engine for research purposes only and does not constitute investment advice. Methodology follows standard CFA / Damodaran frameworks; assumptions are driven by analyst consensus from Financial Modeling Prep and reported financial statements.